Breastfeeding and maternal bone health 10 years postpartum: findings from the ROLO longitudinal cohort study.

Arch OsteoporosOct 28, 2026 (epub)
Clinical ResearchObstetrics & GynecologyEndocrinologyOpen access

Saoirse Kennedy, Kristyn Dunlop, Sophie Callanan et al.

✦ AI-curated · Sources linked

In 30 seconds

This longitudinal cohort analysis examined whether breastfeeding behaviours were associated with maternal bone health 10 years after pregnancy. It included 196 women from the ROLO cohort; DXA measurements were available for 171 and bone turnover markers for 60. Most participants were premenopausal. Breastfeeding duration was not associated with DXA measurements at follow-up. An unadjusted difference in β-CTX-I between women who breastfed for ≥12 months and those who never breastfed was observed (p = 0.038), but the small group size left adjusted analysis underpowered.

Key findings

  • Breastfeeding duration was not associated with DXA measurements at 10-year follow-up.
  • An unadjusted β-CTX-I difference was observed for ≥12 months of breastfeeding versus never breastfeeding (p = 0.038); adjusted analysis was underpowered.

Why it matters

The findings add longitudinal evidence that breastfeeding duration is not associated with adverse maternal bone measurements a decade later. This may help contextualise concerns about lasting skeletal effects, while the exploratory bone turnover marker result remains uncertain and should not be interpreted as evidence of a clinically meaningful difference.

What to keep in mind

DXA data were available for 171 participants and bone turnover marker data for 60; the small group size made adjusted analysis of the exploratory β-CTX-I finding underpowered.

Source

Published in Arch Osteoporos. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchOncology (Medical)

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations.

This international consensus guideline addresses curative-intent management of de novo metastatic nasopharyngeal carcinoma, a population historically treated with palliative intent.

Lancet OncolOct 29, 2026Read summary
Clinical ResearchHematology

Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.

This open-label, multicentre, randomised phase 3 trial compared decitabine plus busulfan-cyclophosphamide (DAC-BuCy) with BuCy conditioning before allogeneic HSCT in 130 patients aged 14–65 years with KMT2A-rearranged…

Lancet HaematolOct 30, 2026Read summary
Clinical ResearchPediatrics

Prone positioning and high-frequency oscillatory ventilation in early paediatric acute respiratory distress syndrome (PROSpect): an international, two-by-two factorial, response-adaptive, phase 3, randomised controlled trial.

PROSpect was an international, two-by-two factorial, phase 3 randomised controlled trial comparing prone with supine positioning and high-frequency oscillatory ventilation (HFOV) with conventional mechanical ventilation…

LancetOct 30, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.